Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Heart Transplant Recipients with Moderate to High-Risk CMV Serostatus
Journal of Cardiac Failure · 2025
DOI: 10.1016/j.cardfail.2025.05.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiac Failure, 2025. Verfasst von Afsana Rahman und 25 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University Irving Medical Center, New York, New York. Hauptthemen laut MEDLINE: Quinazolines, Cytomegalovirus Infections, Acetates, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Cytomegalovirus (CMV) infection post-heart transplantation (HT) is associated with worse outcomes. Antiviral prophylaxis for at-risk patients is the standard of care. Valganciclovir, the most commonly used antiviral drug, is associated with significant adverse events, particularly leukopenia. Letermovir is a CMV-specific antiviral drug with a favorable side effect profile but its efficacy in HT recipients is unclear. This study aims to assess the safety and efficacy of letermovir for CMV prophylaxis in HT recipients. METHODS: This single-center retrospective analysis included HT recipients at our center from January 2020 to September 2023. Patients who were switched to letermovir for CMV prophylaxis for leukopenia/neutropenia on valganciclovir, and remained on letermovir for at least 60 days or developed CMV viremia on letermovir within 60 days of initiation were included. The primary endpoint was the incidence of CMV viremia/disease during letermovir therapy. Secondary endpoints included changes in white blood cell (WBC) count, tacrolimus dosing, and clinically significant acute rejection. RESULTS: A total of 52 patients received letermovir for an average of 8.2 months (range, 1-35 months). The average time from transplantation to letermovir initiation was 9.2 months (range, 0.9-77 months). Eight (15.4%) patients developed breakthrough CMV viremia on letermovir with a median viral load of 205 [IQR, 142.0-367.5] copies/mL; 4 of these patients were converted back to valganciclovir. Overall, 92.3% of patients completed therapy with letermovir. There were no episodes of suspected or biopsy-proven CMV disease. The majority of patients (78%) required dose reductions of tacrolimus following letermovir initiation, with no episodes of tacrolimus toxicity requiring hospitalization. WBC counts increased, on average, from 2.6 to 5.3 × 103 cells/μL (P < .001). CONCLUSION: Letermovir holds promise as an effective and safe alternative to valganciclovir for CMV prophylaxis in HT recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Columbia University Irving Medical Center, New York, New York.
- NewYork-Presbyterian Hospital, New York, New York.
- Weill Cornell Medical College, New York, New York.
- Columbia University Irving Medical Center, New York, New York. Electronic address: nu2126@cumc.columbia.edu.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Rahman, A., Lee, C., Rahman, S., Baranowska, J., Moeller, C. M., Valledor, A. F., Rubenstein, G., Oren, D., Alnatour, A. T., Labarre, B., Taek, K., Bae, D., Raikhelkar, J., Lotan, D., Defilippis, E. M., Yunis, A. A., Fried, J., Latif, F., Yuzefpolskaya, M., …, & Uriel, N. (2025). Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Heart Transplant Recipients with Moderate to High-Risk CMV Serostatus. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2025.05.017
Vancouver
Rahman A, Lee C, Rahman S, Baranowska J, Moeller CM, Valledor AF, et al. Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Heart Transplant Recipients with Moderate to High-Risk CMV Serostatus. Journal of Cardiac Failure. 2025. doi:10.1016/j.cardfail.2025.05.017
BibTeX
@article{Rahman2025,
author = {Rahman, Afsana and Lee, Changhee and Rahman, Salwa and Baranowska, Julia and Moeller, Cathrine M and Valledor, Andrea Fernandez and Rubenstein, Gal and Oren, Daniel and Alnatour, Adel T and Labarre, Brian and Taek, Kyung and Bae, David and Raikhelkar, Jayant and Lotan, Dor and Defilippis, Ersilia M and Yunis, Adil A and Fried, Justin and Latif, Farhana and Yuzefpolskaya, Melana and Colombo, Paolo C and Lin, Edward and Majure, David T and Clerkin, Kevin J and Choe, Jason and Sayer, Gabriel and Uriel, Nir},
title = {Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Heart Transplant Recipients with Moderate to High-Risk CMV Serostatus},
journal = {Journal of Cardiac Failure},
year = {2025},
doi = {10.1016/j.cardfail.2025.05.017}
}
EUVIMED